Genetic Signatures Ltd traded at 0.14 this Tuesday February 3rd. Looking back, over the last four weeks, Genetic Signatures lost 40.43 percent. Over the last 12 months, its price fell by 75.86 percent. Looking ahead, we forecast Genetic Signatures Ltd to be priced at 0.15 by the end of this quarter and at 0.14 in one year, according to Trading Economics global macro models projections and analysts expectations.
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company''s principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.